Safety of Administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Youths and Young Adults with a History of Acute Lymphoblastic Leukaemia and Allergy to PEG-Asparaginase

Catherine Mark[1], Sumit Gupta[2], Angela Punnett[3], Julia Upton[1], Julia Orkin[1], Adelle Atkinson[4], Lindsay Clarke[1], Alice Heisey[1], Christine McGovern[1], and Sarah Alexander[1]

[1]Hospital for Sick Children
[2]The Hospital for Sick Chilren
[3]SickKids
[4]Hospital for Sick Children, Toronto, Canada

June 29, 2021

Abstract

Vaccination is a critical tool in the prevention of COVID-19 infection for individuals and for communities. The mRNA vaccines contain polyethylene glycol (PEG) as a stabilizer. Currently in North America only the BNT162b2 (Pfizer-BioNTech) mRNA vaccine is approved individuals 12 to 17 years of age. Most patients treated with contemporary regimens for acute lymphoblastic leukemia receive Peg-asparaginase and 10-30% will develop allergic reactions. Optimizing access and safety for vaccine administration for these patients critical. This report describes a process developed to support COVID vaccination in a cohort of adolescents and young adults with a history of PEG-asparaginase allergy.

Hosted file

`COVID-19_Vaccine_and_Allergy_to_PEG-Asparaginase_final.docx` available at https://authorea.com/users/422636/articles/528320-safety-of-administration-of-bnt162b2-mrna-pfizer-biontech-covid-19-vaccine-in-youths-and-young-adults-with-a-history-of-acute-lymphoblastic-leukaemia-and-allergy-to-peg-asparaginase

Hosted file

`TABLE 1 Covid vaccine.docx` available at https://authorea.com/users/422636/articles/528320-safety-of-administration-of-bnt162b2-mrna-pfizer-biontech-covid-19-vaccine-in-youths-and-young-adults-with-a-history-of-acute-lymphoblastic-leukaemia-and-allergy-to-peg-asparaginase